Approximately 30-50% of people undergoing allogeneic hematopoietic cell transplantation (HCT) will develop chronic graft-versus-host disease (GVHD), a syndrome characterized by multi-system inflammation and fibrosis that clinically resembles autoimmune diseases. Chronic GVHD is the leading cause of non-relapse mortality in two-year disease free survivors and a major cause of morbidity. In 2005, the NIH convened a consensus conference designed to improve clinical research methods in chronic GVHD. Recommendations from the conference have been published, and are called the """"""""NIH consensus criteria."""""""" During our previous funding period, we assembled a multi-center, longitudinal, observational study of 554 patients who were assessed every six months to test the NIH consensus criteria. We have published 6 papers (12 more submitted or in preparation) evaluating the consensus recommendations. Our results support the recommended definitions for chronic GVHD diagnosis and severity scoring. Specifically, we confirmed the poor prognosis associated with concurrent acute and chronic GVHD (overlap syndrome) and showed a higher non-relapse mortality and lower overall survival associated with moderate-severe chronic GVHD. However, our analyses did not support the recommended NIH measures to assess therapeutic response. In particular, calculated overall NIH response at 6 months correlated poorly with patient and provider-reported responses, and also did not predict subsequent non-relapse mortality and overall survival. Thus, if a new, promising treatment for chronic GVHD were available, the field does not have a validated measure that can serve as a primary endpoint in a clinical trial. To address this critical gap in the field, we propose developing two new tools, the chronic GVHD activity index (CGVHD-AI) and the chronic GVHD severity score (CGVHD-SS). The CGVHD-AI is intended for use as an overall measure of disease activity, so that change in the score from enrollment to follow-up reflects treatment effects. The CGVHD- SS is intended to serve as an intermediate endpoint that predicts eventual treatment success, even if that takes months to years to reach. Eleven centers will enroll 368 patients with chronic GVHD who are just starting initial or secondary therapy. Comprehensive assessments at enrollment and 6 months will collect the candidate patient-reported, provider-reported, and laboratory tests that will be considered for inclusion in the new measures. At 18 months after enrollment, patients will again be assessed with all measures. Using this information, we will develop and validate the CGVHD-AI and CGVHD-SS, thus allowing robust clinical trials in chronic GVHD.

Public Health Relevance

Chronic graft-versus-host disease (GVHD) is a serious complication that occurs when the bone marrow or stem cells from one person are transplanted into another person, usually for the treatment of a blood cancer or other blood disease. Chronic GVHD is the leading cause of death in people who are otherwise cured of their cancers, and it is a major predictor of poor quality of life and impaired ability to function. The goal of this study s to develop better methods to quickly and accurately determine if people are responding to treatment for chronic GVHD.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA118953-07
Application #
8616040
Study Section
Clinical Oncology Study Section (CONC)
Program Officer
Merritt, William D
Project Start
2005-12-01
Project End
2018-02-28
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
7
Fiscal Year
2014
Total Cost
$279,083
Indirect Cost
$77,563
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Yu, Jeffrey; Storer, Barry E; Kushekhar, Kushi et al. (2016) Biomarker Panel for Chronic Graft-Versus-Host Disease. J Clin Oncol 34:2583-90
Aki, S Z; Inamoto, Y; Carpenter, P A et al. (2016) Confounding factors affecting the National Institutes of Health (NIH) chronic Graft-Versus-Host Disease Organ-Specific Score and global severity. Bone Marrow Transplant 51:1350-1353
Merkel, Emily C; Mitchell, Sandra A; Lee, Stephanie J (2016) Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews. Biol Blood Marrow Transplant 22:752-8
Liu, X; Yue, Z; Yu, J et al. (2016) Proteomic Characterization Reveals That MMP-3 Correlates With Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Cell and Lung Transplantation. Am J Transplant 16:2342-51
Palmer, Jeanne; Chai, Xiaoyu; Pidala, Joseph et al. (2016) Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease. Blood 127:160-6
Inamoto, Yoshihiro; Martin, Paul J; Flowers, Mary E D et al. (2016) Genetic risk factors for sclerotic graft-versus-host disease. Blood 128:1516-24
Kariminia, Amina; Holtan, Shernan G; Ivison, Sabine et al. (2016) Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells. Blood 127:3082-91
Palmer, Jeanne; Chai, Xiaoyu; Martin, Paul J et al. (2015) Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease. Haematologica 100:690-5
Martin, Paul J; Lee, Stephanie J; Przepiorka, Donna et al. (2015) National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. Biol Blood Marrow Transplant 21:1343-59
Krupski, Christa; Jagasia, Madan (2015) Quality of Life in the Chronic GVHD Consortium Cohort: Lessons Learned and the Long Road Ahead. Curr Hematol Malig Rep 10:183-91

Showing the most recent 10 out of 45 publications